Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
|Articles|June 10, 2022
Daily Medication Pearl: Tolvaptan (Jynarque)
Author(s)Saro Arakelians, PharmD
Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist .
Advertisement
Indication: Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease. It is also used to treat hyponatremia in patients with heart failure or syndrome of inappropriate antidiuretic hormone.
Insight:
- Dosing: May range from 15 mg to 120 mg, based on the initial titration or target dosage.
- Dosage forms: Tablets 15 mg, 30 mg, 45 mg, 60 mg and 90 mg .
- Adverse events: Most common observed adverse reactions with tolvaptan (incidence >10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria, and polydipsia.
- Mechanism of action: Tolvaptan is a selective vasopressin V2-receptor antagonist with an affinity for the V2-receptor that is 1.8 times that of native arginine vasopressin.
Source:
Advertisement
Related to this article
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
4
Can AI Help Predict Drug Shortages?
5